Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Mammalian target of rapamycin (mTOR) pathway inhibitors, like rapalogs, can induce functional memory CD8 T cells.
• Anticancer vaccines aim to stimulate tumor-specific immune responses.

Purpose of the Study:

• To investigate the combination of temsirolimus with various anticancer vaccines.
• To evaluate the impact of this combination on tumor growth and CD8 T cell responses.
• To assess the role of regulatory T cells (Tregs) in the efficacy of this combined therapy.

Main Methods:

• Utilized diverse cancer vaccine designs (peptides, Shiga toxin vector) and tumor models (melanoma, lung, colon cancer).
• Administered temsirolimus in combination with vaccines.
• Analyzed CD8 T cell phenotypes (central memory markers: CD127+, CD62L+).
• Investigated the effect of regulatory CD4 T cells (Tregs) and employed a CCR4 antagonist to inhibit Tregs.

Main Results:

• Temsirolimus administration decreased tumor growth and boosted vaccine-induced tumor-specific CD8 T cell responses.
• CD8 T cells generated by the combination therapy exhibited central memory characteristics.
• Regulatory T cell (Treg) expansion was found to limit the bi-therapy's efficacy.
• Inhibiting Tregs with a CCR4 antagonist significantly improved the anti-tumor immunity mediated by CD8 T cells.

Conclusions:

• Combining cancer vaccines with temsirolimus promotes memory CD8 T cell generation and enhances anti-tumor immunity.
• Regulatory T cells (Tregs) impede the efficacy of this combined immunotherapy.
• Targeting Tregs alongside vaccine and mTOR inhibitor therapy represents a promising strategy for improving cancer immunotherapy outcomes.